Johnson & Johnson

Aug 15, 2023

FDA Clears J&J’s 2-in-1 Tablet for Prostate Cancer Johnson & Johnson's Janssen Pharmaceutical Companies stated that the US Food and Drug Administration (FDA) had approved AKEEGA (niraparib and abiraterone acetate), the first-and-only dual-action tablet combining a PARP inhibitor including abiraterone ace...

Jun 14, 2021

The global coronavirus has affected almost every industry, and medical devices are no less affected. Even as the first quarter of 2021 has passed, the pandemic hasn’t. No industry has gone unharmed amidst the pandemic, and similarly, the healthcare industry is also witnessing the impact of the resurgence of the vir...

Feb 05, 2019

FDA discards depression drug ALKS 5461 of Alkermes The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine and samidorphan. Alkermes designed the combination to act on the mu- and kappa-opioid receptors that eventually showed im...

Nov 29, 2018

Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures. Canada-based Prometic was asked by the FDA to make and validate process changes for Ryplazim, a c...

Oct 18, 2018

Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis’ eye for USD 12 million. Endocyte was in the stagnation when it held its recovery h...

Oct 16, 2018

FDA approves expanded label for Xarelto of Johnson & Johnson The Food and Drug Administration permitted labelling of blood thinner, Xarelto of Johnson & Johnson, as it can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease (CAD or P...

Oct 04, 2018

Hologic complements Focal Therapeutics to its breast-conserving surgery for USD 125 Million Hologic, a global champion of women's health based in Massachusetts, United States, is taking possession of Focal Therapeutics, a medical device company, for USD 125 million to complement its breast-conserving surgery permit...

May 03, 2018

Horizon Discovery declines Abcam’s USD 367 million takeover bid Horizon Discovery has recently rejected a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique and has issued a strong rejection to the offer of Abcam. Horizon’s board believes that the bid unde...

Nov 07, 2017

Teva looks to sell generics in China through joint venture with Guangzhou Pharma As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that as Teva has said it “has no agreement with...

Apr 17, 2015

Big Pharma Guiding the Stem Cells Future Stem cells (SCs) have been an excitement area of medical research since 1800s. In the mid 1800s it was discovered that cells were basically the building blocks of life and that some cells had the ability to produce other cells and in 1900 scientists had discovered that some...